Pfizer expects significant growth in its revenues from its sales of vaccines and Corona medicines during the year 2022 by up to 50% on an annual basis, as the forecast value is $54 billion, including $32 billion from sales of Corona vaccines, and $22 billion from sales of drugs that treat corona, This is compared to achieving $36.8 billion in coronavirus-related sales in 2021.
According to Arab Net, expectations indicate that corona vaccines and drugs will acquire more than 52% of the company’s revenues this year, estimated at between $98 billion and $102 billion.
Pfizer's business results exceeded earnings estimates, but did not meet revenue trends, as the American pharmaceutical giant recorded $21.98 billion in net profits on revenues of $81.29 billion for 2021.
The Corona vaccine, or what is officially known as Comirnaty from the company's production, took 45% of Pfizer's revenue last year, dwarfing any other drug in the company's huge portfolio.
Pfizer, which developed the vaccine in cooperation with German biotech company Piontech, manufactured more than 3 billion doses of the mRNA vaccine last year, which ended up contributing $36.8 billion to the company's record revenue.
For 2022, Pfizer is currently forecasting $32 billion in sales of its COVID-19 vaccine, in addition to $22 billion in sales of its oral antiviral drug Paxlovid. Both estimates are based on signed or committed supply contracts, as of late January, which means the numbers can be adjusted upwards throughout the year.
For his part, Pfizer CEO Albert Burla said: “In the early days of the Corona pandemic, we committed to using all the resources and expertise at our disposal to help protect the global population from this deadly virus, as well as offering treatments to help avoid the worst outcomes.” p>
"We're putting billions of dollars of capital on the line in pursuit of those goals, and we don't know if these investments will pay off," Burla added. Now, less than two years since we made that commitment, we are proud to say that we have delivered the first FDA-approved vaccine against COVID-19, and the first FDA-approved oral treatment against the pandemic.
